MeSH D003554 - cystinosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Cysteamine | Cystagon | 1994-08-15 | |||
| Horizon Therapeutics Public | Cysteamine | Procysbi | 2027-01-26 | 2013-04-30 | $216.321 M | Q3/22-Q2/23 |
| Chiesi Farmaceutici | Mercaptamine | Procysbi | 2013-09-05 | |||
| Recordati | Cysteamine, Mercaptamine | Cystadrops | 2020-08-19 | |||
| Mercaptamine | Cystagon | 1997-06-23 | ||||
| Leadiant Biosciences | Cysteamine | Cystaran | 2012-10-02 |
Clinical Trials
Historical Success Rate
Phase 1
50%3/6
Phase 2
67%2/3
Phase 3
100%4/4
Approved: 2Overall Success rate: 33%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use